Every year, 5.5 million women have HPV and 200,000 of them are diagnosed with high grade dysplasia a year. Credit: Pavlova Yuliia/Shutterstock.

Tevogen Bio’s AI initiative, Tevogen.AI, has partnered with Microsoft to advance the development of a human papilloma virus (HPV)-specific cytotoxic T cell (CTL) treatment.

By leveraging Microsoft’s advanced tool collection, Tevogen Bio aims to establish an oncology product portfolio, beginning with TVGN 920, its first candidate targeting HPV.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The collaboration involves Tevogen Bio’s creation of a data set containing known proteins in the HPV genome.

This data set is instrumental in identifying CTL targets, crucial for the clinical trial of TVGN 920.

The ExacTcell technology, developed by Tevogen, trains CTLs to identify certain targets and then expands them, potentially expediting the pre-clinical process.

The technology is centred on the selection and expansion of naturally occurring, genetically unmodified clusters of differentiation 8+(CD8+) CTLs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These CTLs are designed to target and destroy unique antigens present in infected or cancerous cells. This approach could lead to a new class of drugs, offering numerous benefits over existing platforms.

Tevogen Bio chief scientific officer Dr Neal Flomenberg stated: “Our ExacTcell technology, which has proven effective in developing SARS-CoV-2-specific CTLs, can be rapidly adapted to create CTL products targeting a wide range of viruses, including HPV.

“While the specific targets may vary between viruses, the platform itself is well-established, enabling a swift response to emerging infectious threats.”

The ExacTcell platform allows for targeting a single, specific human leukocyte antigens molecule in a clinical product. This precision ensures that the specific target peptides are known with certainty.

Many CTLs and those developed with ExacTcell exhibit T cell receptors.

Tevogen Bio CEO and founder Ryan Saadi stated: “With national healthcare cost and patient affordability at the forefront of our presidential candidates’ agendas, the urgency is clear.

“In 2023, US healthcare spending reached an astounding $4.8tn to 17.6% of GDP – highlighting the potential impact on economic prosperity. As the new administration charts its course, Tevogen looks forward to being part of a sustainable solution.”

Every year, 5.5 million women have HPV and 200,000 of them are diagnosed with high-grade dysplasia.